SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
BOULDER — Think Bioscience Inc. recently raised an oversubscribed $55 million Series A round. Think Bioscience Inc. recently raised an oversubscribed $55 million Series A round.
"We are grateful for the collaborative feedback from FDA on the Gemini program, which provides us a clear and expedient path forward for seeking approval of Gemini as a treatment for AKI," said, James ...
Zacks Investment Research on MSN
Are you looking for a top momentum pick? Why Castle Biosciences, Inc. (CSTL) is a great choice
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long ...
Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm ...
Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be ...
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP ...
Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ...
In September 2025, the Company launched AboutNAD®, a next-generation digital platform designed to serve as the leading online resource for scientific advancements in NAD+ research and healthy aging.
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...
PURE Bioscience, Inc. (OTCQB: PURE) (“PURE” or the “Company”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company has appointed Jeff ...
“We delivered an excellent second quarter, with $31.1 million in net sales, up 37% year-over-year, and $3.6 million in net income,” said Niagen Bioscience CEO Rob Fried. “As the pioneers of this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results